Table 1.

Study population baseline characteristics.

	Study Population (n = 20)
Age, years (SD)	62.1 (10.7)
Sex (%)      Female      Male      Other	7 (35.0) 13 (65.0) 0 (0.0)
BMI, kg/m2 (SD)	26.2 (4.4)
Ethnicity (%)      European      Asian      African      Others	20 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Smoking status (%)      Never      Former      Current	7 (35.0) 7 (35.0) 6 (30.0)
Diagnosis (%)      Liver transplantation      Liver cirrhosis      Non-cirrhotic chronic liver disease        (hepatocellular carcinoma or autoimmune hepatitis)	7 (35.0) 9 (45.0) 4 (20.0)
Duration of disease, days (SD)	1825.2 (1539.9)
MELD score (SD); n = 8	12 (4)
Therapy within the last six months (%)      Azathioprine      6-Mercaptopurine      Tacrolimus      Methotrexate      Checkpoint and VEGF inhibitors	1 (5.0) 1 (5.0) 7 (35.0) 0 (0.0) 3 (15.0)
Underlying disease (%)      Cancer      Heart disease      Hypertension      Pulmonary disease      Kidney disease      Diabetes mellitus      Arthritis      Intestinal disease      Hyperlipidemia	5 (25.0) 2 (10.0) 11 (55.0) 1 (5.0) 1 (5.0) 5 (25.0) 1 (5.0) 2 (10.0) 0 (0.0)
SARS-CoV-2 infection since third vaccination (%)	4 (20.0)
Number of SARS-CoV-2 infections ever (%)      0      1      2      3	11 (55.0) 8 (55.0) 0 (0.0) 1 (5.0)
Type of fourth dose vaccine      BNT162b2 XBB.1.5      mRNA-1273.815	18 (90.0) 2 (10.0)
Vaccination schedule doses 1–4 (%)      Homologous      Heterologous	11 (55.0) 9 (45.0)